Eli Lilly Stock Sees RS Rating Rise To 77

Group 1 - Eli Lilly (LLY) stock improved its Relative Strength (RS) Rating from 70 to 77, indicating a stronger market position [2] - The Dow Jones index experienced a significant decline, dropping nearly 400 points, influenced by sell-offs in major stocks including Nvidia, Robinhood, and Tesla [3] Group 2 - Trump announced a reduction in weight-loss drug prices by up to 74% in a deal with Eli Lilly and Novo Nordisk, which may impact market dynamics in the pharmaceutical sector [5] - Eli Lilly was upgraded in the IBD stock rating, reflecting positive market sentiment and potential investment opportunities [5]